12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

AeroVanc regulatory update

Savara said FDA granted Qualified Infectious Disease Product (QIDP) designation for AeroVanc to treat persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis (CF) patients. The compound is now eligible...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >